On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...

Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...